Evaluation of Pyroptosis-related Indicators in the Pathogenesis of Vitiligo:Across-sectional Comparative Study
NCT06261086 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2024-02-15
Summary
Vitiligo is an acquired pigmentary disorder on skin and/or mucosae, which is characterized by death of melanocytes (MCs), affecting 0.5%-2% of the population worldwide (1). It doesn't affect the health of patients but it has marked social pressure and greatly interfere with their quality of life (2,3). It presents with well circumscribed milky white patches that occur secondary to destruction of melanocyte, it may appear at any age and affect both sexes equally.
It can affect ethnic groups and people of all skin types with no predilection (4).
Clinically, several types of vitiligo are distinguished according to the distribution of the achromic lesions. One or more lesions in a dermatomal pattern are characteristic for segmental vitiligo (SV) while this segmental distribution is absent in non-segmental vitiligo (NSV). The latter variety includes both the focal type and the generalized type (5). Numerous previous studies tried to illustrate the pathogenesis behind the disease, but the exact pathophysiology is still not fully understood. It is a multifactorial disease. Factors include, neural theory, oxidative stress theory, autoimmune hypothesis, intrinsic theory, melanocytorrhagy hypothesis (6). Many theories tried to explain the mechanisms of MC destruction in vitiligo. Apoptosis is one of the most widely studied cell death pathways. In addition, the other two forms of cell death, conventional necrosis and autophagy seem to be involved in the death of vitiligo MCs under certain situations. Moreover, new types of regulated cell death including necroptosis, pyroptosis, and ferroptosis may also participate in the pathogenesis (7). Pyroptosis is a highly inflammatory form of necrosis cell death NCD regulated mainly by caspase-1, which is initiated following large supramolecular complex ermed inflammasome activation (8). The inflammasome-activated Caspases then cleave the pyroptosis-inducing protein Gasdermin D (GSDMD), which forms a pore in the plasma membrane and causes cell lysis as well as the secretion of IL-1β typically (9). Another study suggests that inflammasome activation could be a useful marker for assessing disease progression of vitiligo (10). However, the link between vitiligo and inflammasome activation is still unclear. The inflammasome regulates cell death and inflammation via activation of caspase-1 (11). The activation of caspase-1 promotes the secretion of proinflammatory cytokines IL-1β and IL-18, as well as the initiation of pyroptosis (12). So, evaluation of pyroptosis-related indicators (GASDM-D, IL 1β \& IL-18) may help understanding the obscure inflammasome pathway involvement in the pathogenesis of Vitiligo.
Conditions
- Vitiligo
Interventions
- DIAGNOSTIC_TEST
-
evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)
2 ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into plain tubes. Then the samples will be allowed to coagulate during 10-20 minutes. Serum will be obtained by centrifugation at speed of 2000-3000 cycle/min for 20 minutes. Then we collect the supernatant which immediately be frozen at -80°C until analyzed to determine serum levels of pyroptosis-related indicators (GASDM-D, IL 1β \& IL-18). Serum concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit
Sponsors & Collaborators
-
Sohag University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-02-24
- Primary Completion
- 2024-08-24
- Completion
- 2024-08-24
More Related Trials
-
Vitiligo, New Treatment and Serum s100B
NCT06768840 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Questionnaire and Laboratory Data on Vitiligo Vulgaris
NCT01206374 ·Status: COMPLETED
-
Leucotrichia in Vitiligo
NCT03402633 ·Status: COMPLETED
-
Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
NCT03976622 ·Status: UNKNOWN
-
The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity
NCT03741738 ·Status: COMPLETED
-
Building an Assessment Model for Vitiligo Activity and Prognosis Using Peripheral Blood Cytokine Profiles
NCT07298551 ·Status: NOT_YET_RECRUITING
-
Translational Assessment of Vitiligo According to Body Locations
NCT06068218 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Serological Markers of Vitiligo Activity
NCT06731283 ·Status: ACTIVE_NOT_RECRUITING
-
Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
NCT06167408 ·Status: COMPLETED
-
Evaluation of Serum Gasdermin D Level As a Potential Biomarker of Disease Activity in Vitiligo Patients
NCT06584643 ·Status: NOT_YET_RECRUITING
-
The Gut and Skin Microbiome in Vitiligo Disease Progression
NCT03577327 ·Status: RECRUITING
-
Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo
NCT01511965 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Investigating Healthcare Disparities in Vitiligo
NCT06097494 ·Status: COMPLETED
-
Tissue and Serum Level of NLRP1, NLRP3 and Il-18 in Early Stages of mf Patients
NCT06066554 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients
NCT07232238 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo
NCT04320160 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo
NCT05053022 ·Status: COMPLETED ·Phase: NA
-
Stress Response Pathways in Vitiligo
NCT02797574 ·Status: COMPLETED ·Phase: NA
-
IL35 Level in Vitiligo
NCT05980390 ·Status: UNKNOWN
-
Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo
NCT06810869 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Sensory Symptoms in Active Vitiligo
NCT05390164 ·Status: UNKNOWN
-
ERASE VITILIGO Early Repigmentation Approach for Stopping the Evolution of VITILIGO Prospective Multicentric Interventional Study With Blinded Evaluation
NCT04843059 ·Status: COMPLETED ·Phase: NA
-
Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease
NCT02896205 ·Status: COMPLETED ·Phase: PHASE3
-
Insulin Like Growth Factor-1 Against Oxidative Stress in Vitiligo
NCT05812079 ·Status: NOT_YET_RECRUITING
-
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
NCT03249064 ·Status: COMPLETED